- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01789333
Higher Irradiance in Keratoconus Ectasia
Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross- Linking at Higher Irradiances in Patients With Keratoconus or Ectasia
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: MaEdylin Bautista
- Phone Number: 212-305-5922
- Email: mmb2225@columbia.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Edward Harkness Eye Institute-Columbia University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects who have one or both eyes that meet two of the following criteria will be considered candidates for this study:
- 16 years of age or older
Having a diagnosis of progressive keratoconus or pellucid marginal degeneration.
- Characteristic pattern of deformity as analyzed by the Pentacam map.
- Minimal thickness of 350 microns
- The ability to sign a written informed consent
- States a willingness and ability to comply with schedule for follow-up visits
- Subject willing to remove contact lenses prior to evaluation and treatment
Inclusion criteria for ectasia
History of having undergone a keratorefractive procedure and show:
- Steepening by Pentacam study
- Thinning of cornea
- Shift in the position of thinnest portion of cornea
- Unstable refraction with increasing myopia and astigmatism
- Development of irregular astigmatism
- At least two of the above criteria must be present.
Exclusion Criteria:
Subjects meeting any of the following criteria will be excluded from this study:
Subjects meeting any of the following criteria will be excluded from this protocol:
- Eyes classified as either normal or atypical normal,
- Corneal pachymetry ≤ 350 microns at the thinnest point in treatment zone measured by Pentacam.
- A history of delayed epithelial healing.
- Pregnancy (including plan to become pregnant) or lactation during the course of the study
- A known sensitivity to study medications
- Patients with nystagmus or any other condition that is severe enough to prevent steady gaze during the treatment
- Inability to cooperate with diagnostic tests.
- Patients with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing.
- Patients who are unable to remain supine and tolerate a lid speculum.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 9 mw/cm2 at 10 minutes group
30 patients will be treated with UVA light source at 9 mw/cm2 at 10 minutes.
Drug: Riboflavin Dose:1 drop every 2 to 3 minutes for 15 to 20 minutes
|
The device's light emitting diode (LED) is used to deliver a metered dose of Ultraviolet A (UVA) light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking. The aperture setting will be set at 10 mm, and the eye will be irradiated for 10 minutes for the high irradiance exposure of 9 milliwatts (mW)/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes). The speculum is removed and one (1) drop of Riboflavin 0.1% ophthalmic solution will be instilled topically in the eye every 3 minutes for 30 minutes. At the end of the 30 minute riboflavin pre-treatment period, the eye will be examined to assure the presence of a yellow flare in the anterior chamber, indicating riboflavin saturation of the corneal tissue. If the yellow flare is not detected, riboflavin will continue to be instilled until the presence of the yellow flare in the anterior chamber is confirmed. During UVA irradiation, instillation of riboflavin will be continued every 3 minutes. For a 30-minute pre-treatment and 30-minute irradiation, the total dose of riboflavin solution is approximately 32 drops, or 1.6 ml (1 drop = 0.05 ml; 1.6 mL = 1.6 mg riboflavin).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Total Optical Aberrations of the Cornea following Cross-Linking
Time Frame: Baseline to 6 months
|
Assessment of changes in corneal curvature, as analyzed using a Pentacam Scheimpflug Analyzer will be used in all patients.
This allows measurement of corneal thickness, maximum and minimum curvatures and aberration analysis of the cornea as an optical element.
The most significant objective measure of change is the total Higher Order Aberrations of the cornea and the Kmax, or steepest curvature of the cornea.
Analysis of corneal curvature is directly related to improvement in the corneal shape which is directly related to visual function.
|
Baseline to 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stephen Trokel, MD, Columbia University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAF4157
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Keratoconus
-
The Cleveland ClinicUniversity of MarylandEnrolling by invitationKeratoconus | Keratoconus, Unstable | Keratoconus, StableUnited States
-
Eye Hospital Pristina KosovoActive, not recruitingKeratoconus | Keratoconus of Right Eye | Keratoconus, Unstable, Right EyeKosovo
-
Tianjin Eye HospitalRecruitingScansys, Pentacam, Keratoconus, Subclinical KeratoconusChina
-
Tianjin Eye HospitalActive, not recruitingScansys, Pentacam, Corvis ST, Keratoconus, Subclinical KeratoconusChina
-
Heba Allah Nashaat MohamedAssiut UniversityRecruitingKeratoconus, CollagenEgypt
-
Kent Wellish MDNot yet recruitingKeratoconus, Unstable
-
Kasr El Aini HospitalUnknownProgressive KeratoconusEgypt
-
Centre Hospitalier Régional Metz-ThionvilleCompletedProgressive Keratoconus
-
Glaukos CorporationCompletedProgressive KeratoconusUnited States
-
Tianjin Eye HospitalCompletedKeratoconus, StableChina
Clinical Trials on UVA Light with irradiance exposure of 9 mW/cm2
-
University of AarhusUnknownNeonatal Hyperbilirubinemia
-
Glaukos CorporationTerminatedHyperopia | Hyperopic AstigmatismUnited States
-
Oslo University HospitalUnknownKeratoconus | Corneal Ectasia
-
Lithuanian University of Health SciencesCompleted
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompleted
-
L'OrealCompletedSkin Aging | Radiation Tolerance | RhytidsUnited States
-
Peschke Meditrade, GmbHUnknown
-
Federal University of São PauloUnknownProgressive Keratoconus | Cornea DegenerationBrazil
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage IV Cutaneous Melanoma AJCC v6 and v7 | Ocular Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Cutaneous Melanoma | Mucosal Melanoma | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Stage IIIB Uveal Melanoma AJCC v7 | Stage IIIC Uveal Melanoma AJCC v7 | Stage III Acral... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkActive, not recruitingMetastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Colon Cancer AJCC v8 | Stage IV Colon Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC... and other conditionsUnited States